期刊
HAEMATOLOGICA
卷 102, 期 6, 页码 1099-1104出版社
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2016.158303
关键词
-
类别
资金
- Generalitat de Catalunya [AGAUR 2014SGR-1281, 2014SGR-552]
- Instituto de Salud Carlos III [RD12/0036/0071, RD12/0036/0046, PI16/00423]
- Cellex Research Foundation, Barcelona, Spain
- Fondo Europeo de Desarrollo Regional (FEDER)
The presence of circulating plasma cells in patients with multiple myeloma is considered a marker for highly proliferative disease. In the study herein, the impact of circulating plasma cells assessed by cytology on survival of patients with multiple myeloma was analyzed. Wright-Giemsa stained peripheral blood smears of 482 patients with newly diagnosed myeloma or plasma cell leukemia were reviewed and patients were classified into 4 categories according to the percentage of circulating plasma cells: 0%, 1-4%, 5-20%, and plasma cell leukemia with the following frequencies: 382 (79.2%), 83 (17.2%), 12 (2.5%) and 5 (1.0%), respectively. Median overall survival according to the circulating plasma cells group was 47, 50, 6 and 14 months, respectively. At multivariate analysis, the presence of 5 to 20% circulating plasma cells was associated with a worse overall survival (relative risk 4.9, 95% CI 2.6-9.3) independently of age, creatinine, the Durie-Salmon system stage and the International Staging System (ISS) stage. Patients with >= 5% circulating plasma cells had lower platelet counts (median 86x10(9)/L vs. 214x10(9)/L, P<0.0001) and higher bone marrow plasma cells (median 53% vs. 36%, P=0.004). The presence of >= 5% circulating plasma cells in patients with multiple myeloma has a similar adverse prognostic impact as plasma cell leukemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据